Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00003753
Completed
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses a catheter to deliver chemotherapy directly to the liver. Combining more than one drug and giving them in different ways may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of irinotecan combined with hepatic arterial infusion with floxuridine an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Colorectal Cancer, Metastatic Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
NCT00002471
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
06/19/2013
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +3 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00006345
Completed
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2013
Locations: Veterans Affairs Medical Center - Miami, Miami, Florida +10 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Register for Updates
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
NCT00314743
Completed
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous transplant setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2013
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Nausea, Vomiting
Register for Updates
Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block
NCT01538459
Withdrawn
The purpose of this study is to determine the Finger Blood Glucose (sugar) when dexamethasone is added to a local anesthetic for a shoulder nerve block procedure. The investigators hypothesize that there is no increase in plasma glucose when 8 mg of dexamethasone is used as an adjuvant with local anesthetic to interscalene regional anesthesia. By performing finger stick blood glucose measures pre/peri and post operatively the investigators will be able to determine if any such increase exists.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/17/2013
Locations: Newport Hospital, Newport, Rhode Island
Conditions: Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Register for Updates
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT00258245
Completed
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Giv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2013
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Treatment of Acute Lymphoblastic Leukemia in Children
NCT00165178
Completed
The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/23/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
NCT00564889
Completed
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop plasma cells from growing. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cyclophosphamide and dexamethasone may be an effective treatment for primary systemic amyloidosis. PURPOSE: This phase II trial is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
NCT00530270
Terminated
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization. Dexamethasone is a medication that may decrease hospitalization time for people with ACS, but it may also bring about new sickle cell pain. This study will evaluate the effectiveness of a dexamethasone regimen that includes a gradual dose reduction at decreasing hospitalization and recovery time in people with SCD and ACS.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
03/29/2013
Locations: University of California - Davis, Sacramento, California +5 locations
Conditions: Anemia, Sickle Cell
Register for Updates
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
NCT01505088
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Department of Ophthalmology at University of Alabama at Birmingham, Birmingham, Alabama +38 locations
Conditions: Anterior Uveitis
Register for Updates
Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
NCT01027494
Completed
The purpose of this observational study was to evaluate the effects of a topical fluoroquinolone (antibiotic) instilled into the otic (ear) canal to treat Acute Otitis Media through Tympanostomy Tubes (AOMT) on selected bacterial species on the skin near the ear, in the nose, and in the throat.
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
03/14/2013
Locations: Contact Alcon Call Center for Trial Locations, Fort Worth, Texas
Conditions: Acute Otitis Media
Register for Updates
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
NCT00008242
Completed
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of thalidomide, doxorubicin, and dexamethasone in treating patients who have untreated stage II or stage III multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates